ClinicalTrials.gg
CompletedNCT01176851Gly1Updated Oct 29, 2021

Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers

A Phase 1 interventional study of Glycopyrrolate and Glycopyrrolate in Healthy, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the pharmacokinetics, the absolute bioavailability and the lung bioavailability of inhaled Glyco pMDI.

02

Conditions studied

  • Healthy

Keywords

  • None (study in healthy volunteers)
03

In context

Lead sponsor

Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females healthy volunteers aged 18-65 years;
  2. Written obtained before the first trial related activity.
  3. Able to understand the study procedures, the risks involved and ability to be trained to use the devices correctly.
  4. (BMI) between 18.0 and 32.0 kg/m2;
  5. Non- or ex-smokers who smoked \< 5 pack years;
  6. Good physical and mental status;
  7. Normal blood pressure and heart rate;
  8. (ECG)considered as normal;
  9. Results of laboratory tests within the normal ranges.
  10. Lung function measurements within the normal ranges.

Exclusion criteria

Exclusion Criteria:

  1. Blood donation (equal or more than 450 ml) or blood loss less than 8 weeks before inhalation of the study medication;
  2. Pregnant or lactating women or women of , UNLESS they are using one or more of the acceptable methods of . Male subjects not willing to use an acceptable method of contraception.
  3. Positive HIV1 or HIV2 serology;
  4. Positive results from the Hepatitis serology which indicates acute or chronic or ;
  5. Unsuitable veins for repeated venipuncture;
  6. History of substance abuse or drug abuse within 12 months prior to screening visit or with a positive urine drug screen at screening;
  7. abnormal laboratory values suggesting an unknown disease and requiring further clinical investigation;
  8. Clinically significant and uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol;
  9. Participation in another clinical trial less than 8 weeks prior to inhalation of the study medication; participation in another clinical trial using radioactive material within 1 calendar year;
  10. History of to M3 Antagonists or any of the contained in any of the formulations used in the trial;
  11. Any drug treatment, including prescribed or OTC medicines as well as vitamins, homeopathic remedies etc, taken in the 14 days (2 months for enzyme-inducing or enzyme-inhibiting drugs e.g., , phenobarbital, isoniazid) preceding the first intake of the study drug, with the exception of occasional paracetamol (maximum 2 g per day with a maximum of 10 g per 14 days for mild non-excluding conditions).
  12. Treatment within the previous 3 months with any drug known to have a well defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole).
  13. Subjects who refuse to abstain from alcohol or caffeine containing foods or beverages or grapefruit containing foods or beverages from 48 hour prior to the first intake of study medication and for the entire duration of the study.
  14. Heavy caffeine drinker.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Glyco pMDI

    Glyco pMDI 100 µg

    Drug: Glycopyrrolate

  • Experimental
    Glyco pMDI Charcoal

    Glyco pMDI 100 µg + charcoal block

    Drug: Glycopyrrolate

  • Active comparator
    Glyco IV injection

    Glyco solution for injection 100 µg

    Drug: Glycopyrrolate

Interventions

  • Single administration of Glyco pMDI 100 µg

    Also known as: CHF 5259

  • Single administration of Glyco pMDI 100 µg after charcoal ingestion

    Also known as: CHF 5259

  • Single intravenous injection of glycopyrrolate 100 µg

    Also known as: Robinul Injection

06

What researchers measure

Primary outcomes

  1. Plasma and urine pharmacokinetics of glycopyrrolate

    Time frame: over 24 h post dose

Secondary outcomes

  1. Lung function parameters

    Time frame: over 24 h post dose

  2. Cardiovascular parameters

    Time frame: over 24 h post dose

  3. Clinical chemistry and haematology, urinalysis

    Time frame: over 24 h post dose

  4. Adverse Events

    Time frame: during the whole study period

07

Study locations

1 site
  • Medicines Evaluation Unit
    Manchester, M23 9QZ, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2010
First posted
Aug 6, 2010
Start
Jul 2010
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Last update
Oct 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01176851
First posted
Aug 6, 2010
Start date
Jul 2010
Primary completion
Oct 2010
Completion
Oct 2010
Last update
Oct 29, 2021

Study contacts

Dave Singh, MD
principal investigator · Medicines Evaluation Unit

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion